Publication: Incidence and clinical outcomes of non-endometrioid carcinoma of endometrium: Siriraj hospital experience
Issued Date
2014-01-01
Resource Type
ISSN
2476762X
15137368
15137368
Other identifier(s)
2-s2.0-84899890345
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Pacific Journal of Cancer Prevention. Vol.15, No.6 (2014), 2905-2909
Suggested Citation
Atthapon Jaishuen, Kate Kunakornporamat, Boonlert Viriyapak, Mongkol Benjapibal, Pattama Chaopotong, Janjira Petsuksiri, Suwanit Therasakvichya Incidence and clinical outcomes of non-endometrioid carcinoma of endometrium: Siriraj hospital experience. Asian Pacific Journal of Cancer Prevention. Vol.15, No.6 (2014), 2905-2909. doi:10.7314/APJCP.2014.15.6.2905 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/33340
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Incidence and clinical outcomes of non-endometrioid carcinoma of endometrium: Siriraj hospital experience
Other Contributor(s)
Abstract
Background: To study the incidence of non-endometrioid carcinoma of endometrium and compare the clinical characteristics and treatment outcomes with endometrioid carcinoma patients. Materials and Methods: This study included 236 patients with endometrial carcinoma at Siriraj Hospital whom were diagnosed and treated from 2003 through 2006. The clinical characteristics, pathological features, treatment and clinical outcomes were collected from the medical records. The 5-year survival was calculated according to 2009 FIGO staging. Results: Non-endometrioid carcinoma of endometrium accounted for 10.2% of all endometrial carcinomas (24/236 patients). The 5 -year survival rate was significantly lower in the non-endometrioid group compared to the endometrioid group (77.3% vs 96%, p<0.001) and clinical data pointed to greater malignancy. Conclusions: Non-endometrioid carcinoma of endometrium is relative rare but is more aggressive, has more distant metastasis at diagnosis with a worse survival rate than endometrioid carcinoma. Only patients in stage IA with no residual disease on a hysterectomy specimen may not need adjuvant treatment.